All articles by Mukherjee
Ramucirumab misses endpoint for breast cancer but proves effective for gastric cancer
Eli Lilly and Company has announced that its drug ramucirumab has not succeeded in improving the survival rate of metastatic breast cancer patients in its Phase III trial.
GSK hepatitus C treatment granted additional indication in Europe
GlaxoSmithKline’s (GSK) hepatitis C drug Revolade (eltrombopag) has been given marketing authorisation for an additional indication by the European Commission.
UCSD researchers develop new antibiotics detection technique
Biologists at the University of California, San Diego (UC San Diego) have developed a new procedure that can identify and characterise antibiotics.
GSK signs deal with BARDA for anti-anthrax medication
GlaxoSmithKline (GSK) plc has signed a four year contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the US Department of Health and Human Services (HHS), for the supply of its anthrax inhalation treatment, raxibacumab.
European Commission gives marketing approval for prostate cancer drug
US-based biotechnology company Dendreon Corporation has received marketing authorisation from the European Commission (EC) for its prostate cancer treatment, Provenge (sipuleucel-T).
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Multiple sclerosis treatment endorsed by the EMA
Multiple sclerosis (MS) drug alemtuzumab, marketed under the brand name Lemtrada, has been approved by the European Medicines Agency (EMA).
Genzyme’s multiple sclerosis treatment approved by European Commission
Sanofi and its subsidiary Genzyme have been given marketing approval by the European Commission for Lemtrada (alemtuzumab), a treatment for multiple sclerosis.
Columbia Laboratories acquires UK pharma developer
Columbia Laboratories has purchased UK-based Molecular Profiles, a pharmaceutical formula developer and manufacturer, for an estimated $25m.
Roche partners with Inovio Pharma on prostate cancer and hepatitis B therapies
Roche has reached a licence agreement with US-based Inovio Pharmaceuticals to develop and promote Inovio’s multi-antigen DNA immunotherapies for the treatment of prostate cancer and hepatitis B.
FDA approves pancreatic cancer drug Abraxane
US-based Celgene Corporation’s chemotherapy drug Abraxane has received approval by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer, in combination with gemcitabine.